Prospective Randomized Phase-II Trial With Temsirolimus Versus Sunitinib in Previously Untreated Patients With Advanced or Metastatic Non-Clear Cell Renal Carcinoma.
Latest Information Update: 26 Jun 2020
Price :
$35 *
At a glance
- Drugs Sunitinib (Primary) ; Temsirolimus (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 15 Jun 2020 Status changed to discontinued as per Results published in the Oncology Research and Treatment
- 15 Jun 2020 Primary endpoint (Progression free survival (PFS)) has not been met, as per Results published in the Oncology Research and Treatment
- 15 Jun 2020 Results published in the Oncology Research and Treatment